Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Liver Transplantation | Review

An Update on the Management of Budd–Chiari Syndrome

Authors: A. Sharma, S. N. Keshava, A. Eapen, E. Elias, C. E. Eapen

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Abstract

Budd–Chiari syndrome (BCS) is an uncommon condition, caused by obstruction to hepatic venous outflow. It is largely underdiagnosed, and a high index of suspicion is required for any patient with unexplained portal hypertension. The understanding of its etiology and pathology is improving with advances in diagnostic techniques. Recent studies reported an identifiable etiology in > 80% of cases. Myeloproliferative neoplasm (MPN) is the most common etiology, and genetic studies help in diagnosing latent MPN. Better cross-sectional imaging helps delineate the site of obstruction accurately. The majority of BCS patients are now treated by endovascular intervention and anticoagulation which have improved survival in this disease. Angioplasty of hepatic veins/inferior vena cava remains under-utilized at present. While surgical porto-systemic shunts are no longer done for BCS, liver transplantation is reserved for select indications. Some of the unresolved issues in the current management of BCS are also discussed in this review.
Literature
1.
Copelan A, Remer EM, Sands M, Nghiem H, Kapoor B. Diagnosis and management of Budd–Chiari syndrome: an update. Cardiovasc Intervent Radiol. 2015;38:1–12.PubMed
2.
Van Wettere M, Bruno O, Rautou P-E, Vilgrain V, Ronot M. Diagnosis of Budd–Chiari syndrome. Abdom Radiol. 2018;43:1896–1907.
3.
Sarawagi R, Keshava SN, Surendrababu NRS, Zachariah UG, Eapen EC. Budd–Chiari syndrome complicating hydatid cyst of the liver managed by venoplasty and stenting. Cardiovasc Intervent Radiol. 2011;34:S202–S205.PubMed
4.
DeLeve LD, Valla D-C, Garcia-Tsao G. American association for the study liver diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764.PubMed
5.
Zhang W, Qi X, Zhang X, et al. Budd–Chiari syndrome in china: a systematic analysis of epidemiological features based on the Chinese literature survey. Gastroenterol Res Pract. 2015;2015:738548.PubMedPubMedCentral
6.
Perelló A, García-Pagán JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd–Chiari syndrome uncontrolled by medical therapy. Hepatology. 2002;35:132–139.PubMed
7.
Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd–Chiari syndrome. Ann Intern Med. 2009;151:167–175.PubMed
8.
Cheng D, Xu H, Lu Z-J, et al. Clinical features and etiology of Budd–Chiari syndrome in Chinese patients: a single-center study. J Gastroenterol Hepatol. 2013;28:1061–1067.PubMed
9.
Qi X, Wu F, Ren W, et al. Thrombotic risk factors in Chinese Budd–Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 2013;109:878–884.PubMed
10.
Gao X, Gui E, Lu Z, et al. Risk factors of recurrence among 471 Chinese patients with Budd–Chiari syndrome. Clin Res Hepatol Gastroenterol. 2015;39:620–626.PubMed
11.
Eapen CE, Mammen T, Moses V, Shyamkumar NK. Changing profile of Budd–Chiari syndrome in India. Indian J Gastroenterol. 2007;26:77–81.PubMed
12.
Shrestha SM, Okuda K, Uchida T, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol. 1996;11:170–179.PubMed
13.
Eapen C, Elias E. Regional variations in hepatic vascular occlusion. Indian J Gastroenterol. 2005;24:191–192.PubMed
14.
Datta DV, Vashishta S, Samanta AK, Chhuttani PN. Diagnostic value of combined transhepatic venography and inferior vena cavography in chronic Budd–Chiari syndrome. Am J Dig Dis. 1978;23:1031–1041.PubMed
15.
Ki M, Choi HY, Kim K-A, Kim BH, Jang ES, Jeong S-H. Incidence, prevalence and complications of Budd–Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36:1067–1073.PubMed
16.
Goel A, Madhu K, Zachariah U, et al. A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian J Med Res. 2013;137:922–927.PubMedPubMedCentral
17.
Terabayashi H, Okuda K, Nomura F, Ohnishi K, Wong P. Transformation of inferior vena caval thrombosis to membranous obstruction in a patient with the lupus anticoagulant. Gastroenterology. 1986;91:219–224.PubMed
18.
Valla D, Hadengue A, el Younsi M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology. 1997;25:814–819.PubMed
19.
Mancuso A. The ischemic liver cirrhosis theory and its clinical implications. Med Hypotheses. 2016;94:4–6.PubMed
20.
Brancatelli G, Federle MP, Grazioli L, Golfieri R, Lencioni R. Large regenerative nodules in Budd–Chiari syndrome and other vascular disorders of the liver. AJR Am J Roentgenol. 2002;178:877–883.PubMed
21.
Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd–Chiari syndrome: a study in 17 explanted livers. Hepatology. 2003;37:510–519.PubMed
22.
Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587–591.PubMed
23.
Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd–Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–285.PubMedPubMedCentral
24.
Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hemopoietic stem cell defects in Budd–Chiari syndrome. J Hepatol. 1997;26:293–297.PubMed
25.
Pati HP, Dayal S, Srivastava A, Pande GK, Acharya SK. Spectrum of hemostatic derangements, Budd–Chiari syndrome. Indian J Gastroenterol. 2003;22:59–60.PubMed
26.
Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd–Chiari syndrome: a study from Western India. Hepatology. 2001;34:666–670.PubMed
27.
Qi X, Yang Z, Bai M, Shi X, Han G, Fan D. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd–Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther. 2011;33:1087–1103.PubMed
28.
Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–4928.PubMed
29.
30.
Seijo S, Plessier A, Hoekstra J, et al. Good long-term outcome of Budd–Chiari syndrome with a step-wise management. Hepatology. 2013;57:1962–1968.PubMed
31.
Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd–Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18:819–827.PubMed
32.
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.PubMed
33.
Rai P, Kumar P, Mishra S, Aggarwal R. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction. Indian J Gastroenterol. 2016;35:366–371.PubMed
34.
Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. Trop Gastroenterol. 2011;32:279–284.PubMed
35.
Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–85.PubMed
36.
Goulding C, Uttenthal B, Foroni L, et al. The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol. 2008;30:415–419.PubMed
37.
Jain A, Tibdewal P, Shukla A. Calreticulin mutations and their importance in Budd–Chiari syndrome. J Hepatol. 2017;67:1111–1112.PubMed
38.
Li M, De Stefano V, Song T, et al. Prevalence of CALR mutations in splanchnic vein thrombosis: a systematic review and meta-analysis. Thromb Res. 2018;167:96–103.PubMed
39.
Poisson J, Plessier A, Kiladjian J-J, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. 2017;67:501–507.PubMed
40.
Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.PubMedPubMedCentral
41.
Kiladjian J-J, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–4929.PubMed
42.
Mahmoud AE, Wilde JT, Elias E. Budd–Chiari syndrome and factor V Leiden mutation. Lancet. 1995;345:526.PubMed
43.
44.
Bhattacharyya M, Makharia G, Kannan M, Ahmed RPH, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd–Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol. 2004;121:844–847.PubMed
45.
Qi X, Stefano VD, Wang J, et al. Prevalence of inherited antithrombin, protein C, and protein S deficiencies in portal vein system thrombosis and Budd–Chiari syndrome: a systematic review and meta-analysis of observational studies. J Gastroenterol Hepatol. 2013;28:432–442.PubMed
46.
European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.
47.
Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd–Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1801-12.e7.PubMed
48.
Jain A, Shukla A. Prothrombin gene mutation in Budd–Chiari syndrome—the first case report from India. Indian J Gastroenterol. 2018;37:174–175.PubMed
49.
Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–1044.PubMed
50.
Ren W, Li X, Jia J, Xia Y, Hu F, Xu Z. Prevalence of Budd–Chiari syndrome during pregnancy or puerperium: a systematic review and meta-analysis. Gastroenterol Res Pract. 2015;2015:839875.PubMedPubMedCentral
51.
Rautou P-E, Plessier A, Bernuau J, Denninger M-H, Moucari R, Valla D. Pregnancy: a risk factor for Budd–Chiari syndrome? Gut. 2009;58:606–608.PubMed
52.
Pradhan MR, Patel SK, Saraf AA. Informed choice in modern contraceptive method use: pattern and predictors among young women in India. J Biosoc Sci. 2019;2019:1–14.
53.
Shin N, Kim YH, Xu H, et al. Redefining Budd–Chiari syndrome: a systematic review. World J Hepatol. 2016;8:691–702.PubMedPubMedCentral
54.
Hoekstra J, Leebeek FWG, Plessier A, et al. Paroxysmal nocturnal hemoglobinuria in Budd–Chiari syndrome: findings from a cohort study. J Hepatol. 2009;51:696–706.PubMed
55.
Kochhar R, Masoodi I, Dutta U, et al. Celiac disease and Budd–Chiari syndrome: report of a case with review of literature. Eur J Gastroenterol Hepatol. 2009;21:1092–1094.PubMed
56.
Santos LB, Rigueira J, Vilas AP. Infliximab in the treatment of Budd–Chiari syndrome in Behçet’s disease. Reumatismo. 2019;71:163–165.PubMed
57.
Qi X, Han G, Guo X, et al. Review article: the aetiology of primary Budd–Chiari syndrome—differences between the West and China. Alimentary Pharmacol Ther. 2016;2016:44.
58.
Valla D-C. Hepatic venous outflow tract obstruction etiopathogenesis: asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–S211.
59.
Darwish Murad S, Valla D-C, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd–Chiari syndrome. Hepatology. 2004;39:500–508.PubMed
60.
Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd–Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine. 1994;73:21–36.PubMed
61.
Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd–Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.PubMed
62.
Madanagopalan N, Solomon V, Jayanthi V, et al. Clinical spectrum of chronic Budd–Chiari syndrome and surgical relief for ‘coarctation’ of the inferior vena cava. J Gastroenterol Hepatol. 1986;1:359–369.
63.
Sharma A, Goel A, Moses V, et al. Anticoagulating Budd–Chiari syndrome patients presenting with variceal bleed: a retrospective study. J Gastroenterol Hepatol. 2020;
64.
Liu L, Qi X-S, Zhao Y, Chen H, Meng X-C, Han G-H. Budd–Chiari syndrome: current perspectives and controversies. Eur Rev Med Pharmacol Sci. 2016;20:3273–3281.PubMed
65.
Langlet P, Escolano S, Valla D, et al. Clinicopathological forms and prognostic index in Budd–Chiari syndrome. J Hepatol. 2003;39:496–501.PubMed
66.
Das CJ, Soneja M, Tayal S, et al. Role of radiological imaging and interventions in management of Budd–Chiari syndrome. Clin Radiol. 2018;73:610–624.PubMed
67.
68.
Mukund A, Pargewar SS, Desai SN, Rajesh S, Sarin SK. Changes in liver congestion in patients with Budd–Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–687.PubMed
69.
Brancatelli G, Vilgrain V, Federle MP, et al. Budd–Chiari syndrome: spectrum of imaging findings. AJR Am J Roentgenol. 2007;188:W168–W176.PubMed
70.
Garge SS, Keshava SN. Intramural inferior vena cava occlusion: the minaret sign. Egypt J Intern Med. 2016;28:131–132.
71.
Ferral H, Behrens G, Lopera J. Budd–Chiari syndrome. AJR Am J Roentgenol. 2012;199:737–745.PubMed
72.
Cruite I, Tang A, Mamidipalli A, Shah A, Santillan C, Sirlin CB. Liver imaging reporting and data system: review of major imaging features. Semin Roentgenol. 2016;51:292–300.PubMed
73.
Khatri G, Merrick L, Miller FH. MR imaging of hepatocellular carcinoma. J Magn Reson Imaging. 2010;18:421–450.
74.
Gupta P, Bansal V, Kumar-M P, et al. Diagnostic accuracy of Doppler ultrasound, CT and MRI in Budd–Chiari syndrome: systematic review and meta-analysis. Br J Radiol. 2020;93:20190847.PubMedPubMedCentral
75.
Valla D-C. The diagnosis and management of the Budd–Chiari syndrome: consensus and controversies. Hepatology. 2003;38:793–803.PubMed
76.
Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd–Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–89.PubMed
77.
Garcia-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd–Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–815.PubMed
78.
Rautou P-E, Moucari R, Escolano S, et al. Prognostic indices for Budd–Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104:1140–1146.PubMed
79.
De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699.PubMed
80.
Sharma S, Kumar R, Rout G, Gamanagatti SR. Shalimar. Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post-percutaneous endovascular intervention. J Gastroenterol Hepatol. 2020;35:654–662.PubMed
81.
Pieri L, Paoli C, Arena U, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92:187–195.PubMed
82.
Fisher NC, McCafferty I, Dolapci M, et al. Managing Budd–Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut. 1999;44:568–574.PubMedPubMedCentral
83.
Jagtap N, Sharma M, Singh J, et al. Budd–Chiari syndrome: outcomes of endovascular intervention—a single-center experience. Indian J Gastroenterol. 2017;36:209–216.PubMed
84.
Mukund A, Mittal K, Mondal A, Sarin SK. Anatomic recanalization of hepatic vein and inferior vena cava versus direct intrahepatic portosystemic shunt creation in Budd–Chiari syndrome: overall outcome and midterm transplant-free survival. J Vasc Interv Radiol. 2018;29:790–799.PubMed
85.
Rathod K, Deshmukh H, Shukla A, et al. Endovascular treatment of Budd–Chiari syndrome: single center experience. J Gastroenterol Hepatol. 2017;32:237–243.PubMed
86.
Tripathi D, Sunderraj L, Vemala V, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd–Chiari syndrome. Liver Int. 2017;37:111–120.PubMed
87.
Zhang W, Wang Q-Z, Chen X-W, et al. Budd–Chiari syndrome in China: a 30-year retrospective study on survival from a single center. World J Gastroenterol. 2018;24:1134–1143.PubMedPubMedCentral
88.
Shalimar KA, Kedia S, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment Pharmacol Ther. 2016;43:1154–1167.PubMed
89.
Bi Y, Chen H, Ding P, Zhou P, Ren J, Han X. Percutaneous transhepatic hepatic vein angioplasty in Budd–Chiari syndrome after transvenous failure. J Laparoendosc Adv Surg Tech A. 2018;28:1346–1351.PubMed
90.
Keshava SN, Moses V, Surendrababu NRS. Cannula-assisted and transabdominal ultrasound-guided hepatic venous recanalization in Budd–Chiari syndrome: a novel technique to avoid percutaneous transabdominal access. Cardiovasc Intervent Radiol. 2009;32:1257.PubMed
91.
Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome. Gut. 2006;55:878–884.PubMedPubMedCentral
92.
Mammen T, Keshava S, Eapen CE, et al. Intrahepatic collateral recanalization in symptomatic Budd–Chiari syndrome: a single-center experience. J Vasc Interv Radiol. 2010;21:1119–1124.PubMed
93.
Wang Q, Li K, He C, et al. Angioplasty with versus without routine stent placement for Budd–Chiari syndrome: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:686–697.PubMed
94.
Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology. 2005;41:386–400.PubMed
95.
Keshava SN, Kota GK, Mammen T, et al. Direct intrahepatic cavo-portal shunts in Budd–Chiari syndrome: role of simultaneous fluoroscopy and trans-abdominal ultrasonography. Indian J Gastroenterol. 2006;25:248–250.PubMed
96.
Hatzidakis A, Galanakis N, Kehagias E, et al. Ultrasound-guided direct intrahepatic portosystemic shunt in patients with Budd–Chiari syndrome: short- and long-term results. Interv Med Appl Sci. 2019;9:86–93.
97.
Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut. 2011;60:846.PubMed
98.
Mammen S, Keshava SN, Kattiparambil S. Acute portal vein thrombosis, no longer a contraindication for transjugular intrahepatic porto-systemic shunt (TIPS) insertion. J Clin Exp Hepatol. 2015;5:259–261.PubMed
99.
Ahmed M, Keshava SN, Moses V, et al. Transjugular intrahepatic portosystemic shunt through the strut of a previously placed stent: technical feasibility and long-term follow-up results. Cardiovasc Intervent Radiol. 2018;41:1794–1798.PubMed
100.
Tripathi D, MacNicholas R, Kothari C, et al. Good clinical outcomes following transjugular intrahepatic portosystemic stent-shunts in Budd–Chiari syndrome. Aliment Pharmacol Ther. 2014;39:864–872.PubMed
101.
Gp K, Ra B, Hs K. Catheter-directed thrombolysis and thrombectomy for the Budd–Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol. 2006;17:383–387.
102.
Clark PJ, Slaughter RE, Radford DJ. Systemic thrombolysis for acute, severe Budd–Chiari syndrome. J Thromb Thrombolysis. 2012;34:410–415.PubMed
103.
Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd–Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004;40:172–180.PubMed
104.
Zhang Q, Xu H, Zu M, et al. Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd–Chiari syndrome complicated by thrombosis. Exp Therapeut Med. 2013;6:1015–1021.
105.
Zhang QQ, Xu H, Zu MH, et al. Strategy and long-term outcomes of endovascular treatment for Budd–Chiari syndrome complicated by inferior vena caval thrombosis. Eur J Vasc Endovasc Surg. 2014;47:550–557.PubMed
106.
Hayek G, Ronot M, Plessier A, et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd–Chiari syndrome. Radiology. 2016;283:280–292.PubMed
107.
Klein AS, Molmenti EP. Surgical treatment of Budd–Chiari syndrome. Liver Transpl. 2003;9:891–896.PubMed
108.
Orloff MJ, Isenberg JI, Wheeler HO, Daily PO, Girard B. Budd–Chiari syndrome revisited: 38 years’ experience with surgical portal decompression. J Gastrointest Surg. 2012;16:286–300.PubMed
109.
Parekh J, Matei VM, Canas-Coto A, Friedman D, Lee WM, Acute Liver Failure Study Group. Budd–Chiari syndrome causing acute liver failure: a multicenter case series. Liver Transpl. 2017;23:135–42.
110.
Ara C, Akbulut S, Ince V, Karakas S, Baskiran A, Yilmaz S. Living donor liver transplantation for Budd–Chiari syndrome: overcoming a troublesome situation. Medicine. 2016;95:e5136.PubMedPubMedCentral
111.
Ulrich F, Pratschke J, Neumann U, et al. Eighteen years of liver transplantation experience in patients with advanced Budd–Chiari syndrome. Liver Transpl. 2008;14:144–150.PubMed
112.
Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd–Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–528.PubMed
113.
O’Grady JG. Budd–Chiari syndrome and acute liver failure: a complex condition requiring a rapid response. Liver Transpl. 2017;23:133–134.PubMed
114.
Jayalakshmi VT, Bernal W. Update on the management of acute liver failure. Curr Opin Crit Care. 2020;26:163–170.PubMed
115.
116.
Rautou P-E, Angermayr B, Garcia-Pagan J-C, et al. Pregnancy in women with known and treated Budd–Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54.PubMed
117.
Ren W, Qi X, Yang Z, Han G, Fan D. Prevalence and risk factors of hepatocellular carcinoma in Budd–Chiari syndrome: a systematic review. Eur J Gastroenterol Hepatol. 2013;25:830–841.PubMed
118.
Moucari R, Rautou P-E, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd–Chiari syndrome: characteristics and risk factors. Gut. 2008;57:828–835.PubMed
119.
Plessier A, Rautou P-E, Valla D-C. Management of hepatic vascular diseases. J Hepatol. 2012;1:S25–S38.
120.
Kathuria R, Srivastava A, Yachha SK, Poddar U, Baijal SS. Budd–Chiari syndrome in children: clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014;26:1030–1038.PubMed
121.
Meena BL, Khanna R, Sood V, et al. Budd–Chiari syndrome in children—outcome following radiological intervention. J Clin Exp Hepatol. 2018;8:S120–S121.
122.
Shukla A, Bhatt P, Gupta DK, et al. Budd–Chiari syndrome has different presentations and disease severity during adolescence. Hepatol Int. 2018;12:560–566.PubMed
123.
Sharma VK, Ranade PR, Marar S, Nabi F, Nagral A. Long-term clinical outcome of Budd–Chiari syndrome in children after radiological intervention. Eur J Gastroenterol Hepatol. 2016;28:567–575.PubMed
124.
Zhang F, Wang C, Li Y. The outcomes of interventional treatment for Budd–Chiari syndrome: systematic review and meta-analysis. Abdom Imaging. 2015;40:601–608.PubMed
Metadata
Title
An Update on the Management of Budd–Chiari Syndrome
Authors
A. Sharma
S. N. Keshava
A. Eapen
E. Elias
C. E. Eapen
Publication date
01-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06485-y

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue

EDITORIAL

Breath Test or Duodenal Aspirate for Small Intestinal Bacterial Overgrowth: Still No Breath of Fresh Air

Original Article

Inhibition of MicroRNA-302c on Stemness of Colon Cancer Stem Cells via the CARF/Wnt/β-Catenin Axis

Original Article

Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan

Original Article

Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

Original Article

Endoscopic Retrograde Cholangiopancreatography During the COVID-19 Pandemic: Effects of Enhanced Personal Protective Equipment

Original Article

Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits